SAN FRANCISCO, CA and NORTHBROOK, IL -- (Marketwire) -- 02/25/13 -- Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (TSE: 4503), announced that the companies are providing additional support to the Chronic Disease Fund (CDF). CDF uses charitable donations to help eligible men with metastatic castration resistant prostate cancer that need financial assistance paying their out-of-pocket expenses, including co-pays or co-insurance. CDF is an independent, non-profit organization that provides financial assistance to help eligible patients obtain prescription medications. Independent of Astellas and Medivation, CDF determines how to distribute donations and evaluate patient eligibility.
"Astellas and Medivation are committed to helping patients access medicines their physicians believe are necessary. Organizations like CDF provide an invaluable resource to patients in need and we applaud their efforts," said Mark Reisenauer, Vice President, Astellas Oncology.
"We are proud to support non-profit charitable organizations, such as the CDF, that are striving to provide the greatest level of access, care and assistance to patients to help them obtain the medicines that they need," said Melissa Abel, Vice President at Medivation, Inc.
Information about programs established to help patients gain access to approved medications can be found at www.astellasaccess.com.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.
Astellas Pharma US, Inc., located in Northbrook, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in oncology, and has several oncology products on the market and compounds in development. Astellas is proud to be an award recipient of the CEO Gold Standard Accreditation from the CEO Roundtable on Cancer. For more information on Astellas Pharma Inc., please visit our website at www.astellas.us.
Chief Business & Financial Officer
Senior Director, Investor Relations
Sam Brown, Inc (media for both companies)
|Medivation and Astellas Provide Update on PREVAIL (2013/4/1)|
|Precision Biopsy Appoints Amir Tehrani as Chief Executive Officer and Announces Successful Completion of Phase I Clinical Trial in Prostate Cancer Patients (2013/2/11)|
|Prostate Cancer Patient Receives First Treatment Using Latest Version of Vitesse Real-Time Brachytherapy Planning System from Varian Medical Systems (2013/4/16)|
|Puma Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients (2013/2/20)|
|Genomic Health Announces Availability of Oncotype DX® Prostate Cancer Test with Potential to Triple the Number of Patients Who Can Confidently Choose Active Surveillance and Avoid Side Effects of Invasive Treatments (2013/5/8)|
|OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer (2013/5/1)|
|Myriad to Present New Molecular Data for Patients With Prostate Cancer at the American Urological Association 2013 Annual Meeting (2013/5/2)|
|Transgenomic Signs Collaboration Agreement with Amgen for Development of CE-IVD CRC RAScan™ Mutation Detection Tests for Patients with Metastatic Colorectal Cancer (2013/5/6)|
|Transgenomic Announces Global Availability of CRC RAScan™ Mutation Detection Test for Use in Patients with Metastatic Colorectal Cancer to Help Identify Appropriate Treatment (2013/5/16)|
|Endocyte's Investigational Diagnostic Imaging Agent Etarfolatide Identifies Ovarian Cancer and Non-Small Cell Lung Cancer Patients Most Likely to Benefit From Folate Receptor-Targeted Treatment, New Analysis Shows (2013/3/1)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.